RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery. (1st January 2020)

• Record Type: Journal Article
• Authors: Hao, Rubin; Sun, Bixi; Yang, Lihua; Ma, Chun; Li, Shuling
• Is Part Of: Drug delivery. Volume 27:Number 1(2020)
• Page Start: 772
• Page End: 781
• Publication Date: 2020-01-01
• Subjects: Nose-to-brain -- Ischemic brain injury -- miRNA -- RVG29; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2020.1760960
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Effective nose-to-brain delivery needs to be developed to treat neurodegenerative diseases. Regulating miR-124 can effectively improve the symptoms of ischemic brain injury and provide a certain protective effect from brain damage after cerebral ischemia. We used rat models of middle cerebral artery occlusion (t-MCAO) with ischemic brain injury, and we delivered RVG29-NPs-miR124 intranasally to treat neurological damage after cerebral ischemia. Rhoa and neurological scores in rats treated by intranasal administration of RVG29-PEG-PLGA/miRNA-124 were significantly lower than those in PEG-PLGA/miRNA-124 nasal administration and RVG29-PLGA/miRNA-124 nasal administration group treated rats. These results indicate that the nose-to-brain delivery of PLGA/miRNA-124 conjugated with PEG and RVG29 alleviated the symptoms of cerebral ischemia-reperfusion injury. Thus, nasal delivery of RVG29-PEG-PLGA/miRNA-124 could be a new method for treating neurodegenerative diseases.